Elan's Zonegran deal goes through

Elan has completed the sale of its North American and European interests in Zonegran to Eisai Inc. for €109m.

Elan's Zonegran deal goes through

Elan has completed the sale of its North American and European interests in Zonegran to Eisai Inc. for €109m.

The pharmaceutical firm may also earn purchase payments of up to €92.24m when generic zonisamide is introduced in the US, which includes up to €21m on receiving marketing approval for Zonegran in Europe.

You have reached your article limit. Already a subscriber? Sign in

Continue reading for €5

Unlock unlimited access and exclusive benefits

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited